Article info
PDFPerspective
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
- James Raftery, Wessex Institute for Health R&D, Mailpoint 728, Medical School, University of Southampton, Southampton SO16 7PX, UK; raftery{at}soton,.ac.uk
Citation
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Publication history
- Accepted March 14, 2007
- First published April 12, 2007.
Online issue publication
August 20, 2007
Article Versions
- Previous version (12 April 2007).
- Previous version (11 May 2007).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2007 BMJ Publishing Group